ADC Therapeutics S.A.
ADCTAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 4, 2026 | Stephens | Sudan Loganathan | $5.00(+244%) | $1.46 | TheFly |
| Jun 4, 2026 | RBC Capital | $2.00(-35%) | $3.08 | TheFly | |
| Dec 3, 2025 | RBC Capital | Gregory Renza | $5.00(+26%) | $3.96 | StreetInsider |
| Nov 12, 2025 | Guggenheim | Michael Schmidt | $10.00(+152%) | $3.97 | StreetInsider |
| May 7, 2024 | H.C. Wainwright | Robert Burns | $8.00(+80%) | $4.45 | StreetInsider |
| Mar 13, 2024 | Jefferies | Kelly Shi | $13.00(+233%) | $3.90 | StreetInsider |
| Nov 14, 2022 | Morgan Stanley | $7.00(+71%) | $4.10 | Benzinga | |
| Sep 9, 2022 | Morgan Stanley | Matthew Harrison | $11.00(+69%) | $6.52 | TheFly |
| Aug 22, 2022 | H.C. Wainwright | $20.00(+138%) | $8.42 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Guggenheim | maintain | Buy | Aug 17, 2026 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Jun 8, 2026 |
| RBC Capital | downgrade | Outperform →Sector Perform | Jun 4, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 5, 2026 |
| RBC Capital | maintain | Outperform | May 5, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 23, 2026 |
| HC Wainwright & Co. | maintain | Buy | Oct 16, 2025 |
| Guggenheim | maintain | Buy | Aug 13, 2025 |
| RBC Capital | maintain | Outperform | Jun 20, 2025 |
| Guggenheim | maintain | Buy | Jun 13, 2025 |
| RBC Capital | maintain | Outperform | May 15, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 31, 2025 |
| Guggenheim | maintain | Buy | Mar 31, 2025 |
| Cantor Fitzgerald | maintain | Overweight | Mar 7, 2025 |
| Stephens & Co. | maintain | Overweight | Feb 24, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 6, 2025 |
| Guggenheim | maintain | Buy | Dec 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 11, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 8, 2024 |
| RBC Capital | maintain | Outperform | Aug 7, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 7, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 15, 2024 |
| RBC Capital | maintain | Outperform | Mar 14, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 6, 2024 |
| RBC Capital | maintain | Outperform | Feb 26, 2024 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.11 | $-0.22 | $19.2M | $18.9M |
| May 4, 2026 | $-0.21 | $-0.19 | $20.9M | $20.0M |
| Mar 10, 2026 | $-0.04 | $-0.32 | $23.1M | $22.3M |
| Nov 10, 2025 | $-0.30 | $-0.40 | $16.4M | $16.8M |
| Aug 12, 2025 | $-0.50 | $-0.36 | $18.8M | $17.9M |
| May 14, 2025 | $-0.36 | $-0.38 | $23.0M | $17.7M |
| Mar 27, 2025 | $-0.29 | $-0.38 | $16.9M | $19.0M |
| Nov 7, 2024 | $-0.42 | $-0.36 | $18.5M | $18.4M |
News
ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Data at ASH and Strategic Financial Restructuring Transcript
ADC Therapeutics NYSE: ADCT outlined new lymphoma data and plans for further studies of its cancer drug ZYNLONTA, while reporting preliminary third-quarter sales of approximately $21 million and an expected cash runway into 2029.
ZYNLONTA data to be featured across 5 oral presentations and multiple posters Phase 1b LOTIS-7 abstract data demonstrates an 88.7% ORR and 75.3% CR with ZYNLONTA plus glofitamab across the 97 efficacy-evaluable r/r DLBCL patients Phase 2 marginal zone lymphoma IIT abstract shows robust and durable 93% ORR and 74.4% CRR with ZYNLONTA monotherapy Company to host conference call today at 4:15 p.m. EST LAUSANNE, Switzerland, Nov. 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial…
LAUSANNE, Switzerland, Nov. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two upcoming investor conferences in November: Guggenheim Third Annual Healthcare Innovation Conference Date: Tuesday, November 10, 2026Presentation Time: 1:30 p.m. ESTFormat: Fireside ChatSpeaker: Ameet Mallik, Chief Executive OfficerLocation: Boston, MATo register for the webcast, cli…
LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on November 2, 2026. ("Grant").
LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company will report full financial results for the third quarter of 2026 through a press release on Monday, November 9, 2026. The press release will be available in the News section of the Company's website, https://ir.adctherapeutics.com/news.
Licensing partner, Tanabe Pharma, filed for Japanese approval of ZYNLONTA (MT-2111) for relapsed or refractory DLBCL based on encouraging Japanese Phase 1/2 clinical results Tanabe Pharma entered into exclusive sublicensing agreement with Nippon Shinyaku, bringing established Japanese oncology expertise and commercial capabilities to support potential introduction in Japan Supports anticipated regulatory and commercial milestones for ADC Therapeutics LAUSANNE, Switzerland, Oct. 29, 2026 /PRNewsw…
$86.6 Million Private Placement announced, with participation from new and existing investors, extending expected cash runway into 2029 HealthCare Royalty financing agreement amended, removing change-of-control payment Senior secure loan refinanced, decreasing principal to $50M with bullet payment in August 2029 and no minimum liquidity LAUSANNE, Switzerland, Oct. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody dru…
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
LAUSANNE, Switzerland, Sept. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, NY, on Friday, September 11, 2026, at 9:10 a.m.
ADC Therapeutics NYSE: ADCT reported second-quarter 2026 net product revenue of $18.6 million for ZYNLONTA, up from $18.1 million in the prior-year period, while executives said the treatment's commercial performance remained broadly consistent with recent quarters.
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.5 per share a year ago.
Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financ…